Skip to main content
Premium Trial:

Request an Annual Quote

Promega and Accelr8 Technology, Northwestern Ontario Technology Centre, and Agilent Technologies


Promega Licenses Accelr8's Microarray Surface Chemistry

Accelr8 Technology said this week that it may license its OptiChem surface chemistry to Promega for use in microarraying slides.

According to documentation filed with the SEC this week, Promega will evaluate Accelr8's technology under a feasibility testing agreement before it agrees to distribute the slides to third parties. The agreement, set to expire in Sept. 2006, calls for Promega to pay Accelr8 $49,000 for the initial evaluation period, which, if successful, will result in an official licensing agreement. Any enhancements developed during the testing period will be owned by Accelr8. Inventions developed afterwards will be jointly owned by Accelr8 and Promega.

The OptiChem coatings are thin organic films that provide selective biomolecule binding with very low non-specific adsorption, according to the company.

Northwestern Ontario Technology Centre Opens New $1.4M Lab

The Northwestern Ontario Technology Centre, a joint effort of Genesis Genomics and Lakehead University's Paleo-DNA laboratory, opened a new $1.4 million microarray lab last week, according to a report a local newspaper.

Ontario's Chronicle Journal reported that the new lab, opened in Thunder Bay, will be used by researchers for work in pathogen, cancer, agricultural, and industrial research. The facility and its equipment was purchased through a partnership with LU, along with grants from FedNor and the Northern Ontario Heritage Fund, the paper reported.

Agilent's Sale of Semiconductor Unit Delayed to December

Agilent Technologies said last week it expects to close the sale of its semiconductor operations to private equity firms Kohlberg Kravis Roberts & Co. and Silver Lake Partners "on or near" Dec. 1, which is later than originally planned.

When Agilent announced the sale in August, it said the deal would close by Oct. 31. Agilent did not mention the delay in a statement last week, but it said that the "target closing date is timed to position the companies to provide a seamless transition for customers, suppliers, and employees in the 19 countries in which [the Semiconductor Products Group] operates."

Agilent said in August that it will sell its chip unit to the buyout firms, which will be equal partners in the venture, for $2.66 billion. Kohlberg and Silver Lake said at the time that their purchase will create the world's largest privately held independent semiconductor company.

Agilent previously said it plans to use proceeds from the deal for a $4 billion share repurchase program.


The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.